PCUR 101

Drug Profile

PCUR 101

Alternative Names: PCUR-101

Latest Information Update: 18 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pellficure Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 01 Jul 2017 Phase-I clinical trials in Prostate cancer (Hormone refractory, Metastatic disease, Combination therapy) in USA (PO) (NCT03137758)
  • 24 Apr 2017 Pellficure Pharmaceuticals plans a phase I trial for Prostate cancer (Metastatic disease, Hormone refractory, Combination therapy) in USA (PO) (NCT03137758)
  • 24 Apr 2017 Preclinical trials in Prostate cancer in USA prior to April 2017 (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top